Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Melanoma immunotherapy faces challenges with rising resistance to existing treatments.
• Individualized immunotherapy targeting specific mutations offers a promising alternative.
• Current mutanome-based approaches encounter practical hurdles in sequencing, target selection, and manufacturing.

Purpose of the Study:

• To explore the potential of artificial intelligence (AI) in refining mutanome-based melanoma immunotherapy.
• To address the limitations of current individualized immunotherapy strategies.

Main Methods:

• Review of current research on mutanome-based immunotherapy for melanoma.
• Analysis of AI's role in developing immune-stimulating vaccines and improving adoptive cell therapy.
• Identification of challenges and limitations in AI application for mutanome-based therapies.

Main Results:

• AI can potentially refine mutanome-based immunotherapy by aiding in vaccine development and treatment optimization.
• AI offers a pathway to overcome practical obstacles in personalized melanoma treatment.
• Current AI applications are limited by data availability, cost, and inference capabilities.

Conclusions:

• AI holds significant potential for advancing individualized melanoma immunotherapy by leveraging mutanome data.
• Further research is critical to overcome AI limitations and fully realize its benefits in melanoma management.
• Mutanome-based, AI-driven immunotherapy represents a crucial future direction for melanoma treatment.